Autologous graft-versus-host disease induction in advanced breast cancer: Role of peripheral blood progenitor cells

British Journal of Cancer

Volumn 83, Issue 11, 2000, Pages 1405-1411

  Van Der Wall, E ^a   Horn, T ^a   Bright, E ^a   Passos Coehlo, J L ^a   Bond, S ^a   Clarke, B ^a   Altomonte, V ^a   McIntyre, K ^a   Vogelsang, G ^a   Noga, S J ^a   Davis, J M ^a   Thomassen, J ^a   Ohly, K V ^a   Lee, S M ^a   Fetting, J ^a   Armstrong, D K ^a   Davidson, N E ^a   Hess, A D ^a   Kennedy, M J ^a  

^a NONE   (United States)

Author keywords

Autoreactive T cells; Breast cancer; CLIP; Cyclosporine; MHC class II; Peripheral stem ceils

Indexed keywords

ANTIHISTAMINIC AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GAMMA INTERFERON; PREDNISONE; STEROID; THIOTEPA;

ADULT; ARTICLE; BLOOD; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOTOXICITY; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STEM CELL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; CYCLOSPORINE; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; KILLER CELLS, NATURAL; LYMPHOCYTES; MIDDLE AGED; PHYTOHEMAGGLUTININS; SURVIVAL ANALYSIS; THIOTEPA;

EID: 0033675884     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1499     Document Type: Article

References (29)

1. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America
2. HLADR antigens on differentiating human mammary gland epithelium and breast tumours
3. High-dose chemotherapy in metastatic breast cancer
4. Histologic comparison of autologous graft-versus-host reaction and cutaneous eruption of lymphocyte recovery
5. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial
6. Developing and shedding inhibitions: How MHC Class II molecules reach maturity
7. Granulocyte colony-stimulating factor 'mobilized' peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy
8. The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK506
9. Age related factors in Cyclosporine-induced syngeneic graft-vs-host disease: Regulatory role of marrow derived T lymphocytes
10. Characterization of the autoreactive T cell repertoire in cyclosporine-induced syngeneic graft-versus-host disease: A highly conserved repertoire mediates autoaggression
11. Cytotoxic T cells overcome BRL-ABL-mediated resistance to apoptosis
12. Kinetics of natural killer cell cytotoxicity during the graft-versus-host reaction: Relationship between natural killer cell activity, T and B cell activity, and development of histopathological alterations
13. Graft-versus-host disease in cyclosporin A treated rats after syngeneic and autologous bone marrow reconstitution
14. Clinical manifestations of graft versus host disease in human recipients of marrow from HLA matched sibling donors
15. Effector mechanisms in cyclosporine A-induced syngeneic graft-versus-host disease
16. Specificity of effector T lymphocytes in autologous graft-versus-host disease: Role of the major histocompatibility complex class II invariant chain peptide
17. Specificity of effector mechanisms in syngeneic graft-vs-host disease: Recognition of the MHC class II invariant chain peptide (CLIP)
18. Complexity of effector mechanisms in Cyclosporine-induced syngeneic graft-vs-host disease. Biology of Blood and Marrow
19. Reappraisal of histologic features of the acute cutaneous graft-versus-host reaction based on an allogeneic rodent model
20. Induction of graft-versus-host disease after autologous bone marrow transplantation
21. Cyclosporine
22. Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer
23. Phase I trial of Interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer
24. Autologous graft-versus-host disease with cyclosporin A after peripheral blood transplantation: Analysis of factors affecting induction
25. Cyclosporine-induced autologous graft versus host disease: Assessment of cytolytic effector mechanisms and the Vβ T-cell receptor repertoire
26. The skin biopsy in the diagnosis of acute graft-versus-host disease in man
27. Antileukemic effects of graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation
28. Flow cytometric analysis of tumor infiltrating lymphocyte activation and tumor cell MHC class I and II expression in breast cancer patients
29. Much ado about not enough data: High-dose chemotherapy with autologous stem cell rescue for breast cancer